benefit-transfer: practice and prospects workshop 22 november 2007 applications of...
TRANSCRIPT
Benefit-Transfer: Practice and Prospects
Workshop
22 November 2007
Applications of Benefit–Transfer in Health
Kees van GoolCentre for Health Economics Research and Evaluation
University of Technology Sydney
2
Outline
• Setting the scene– Economic evaluation and health care policy– Economic evaluation and benefit transfer in health
• Examples: – Screening for cystic fibrosis – Health impact of noise– Cancer treatment protocols
• Conclusions
Setting the scene
4
Economic evidence and health care policy• Evidence of use at a central level, e.g.
– PBAC/MSAC in Australia
– NICE in the UK
– CDR in Canada
• Very limited evidence of use at a local level (e.g. public hospitals)
5
Central level use of economic evidence• Pharmaceutical Benefits Scheme (PBS):
– Australia’s most famous example of economic evaluation use
– Used to make decisions about which (new) drugs to list on the PBS and receive public subsidies.
– Mandatory use of economic evidence since 1993 (world first)
– Formal nexus between decision-making and economic evidence
– Pharmaceutical Benefits Advisory Committee (PBAC) recommendation binds the Minister for Health:
• Minister cannot list drugs that have been rejected by PBAC• Minister can reject drugs that have been recommended by
PBAC
6
Central level use of economic evidence• Applicants (drug companies) conduct economic
evaluation based on guidelines published by PBAC– Focus on “how much it would cost to achieve additional health
outcomes with the new therapy compared with the existing therapy that would be replaced”
– Australian context
• Use of randomised clinical control trial data, but:– Lack of resource data (estimation)– Insufficient duration (extrapolation)– Trial population differ from real population (application)– Non-patient-relevant outcomes of treatment (transformation)
Translation (akin to benefit-transfer)
7
Central level use of economic evidence
• Independent consultants check modeling• Department of Health re-checks• In 2006, PBAC made 187 decisions (137
positive recommendations)• PBAC administrative costs around $11m
– $60,000 per decision
• PBAC economic evidence not publicly available due to commercial-in-confidence
8
Local level use of economic evidence
• Hospitals and local health regions make many resource allocation decisions
• Very little use of economic evidence at this level– Lack health economics expertise/resources
at local level– Perception of bias in studies– Lack of relevance to local setting– Budget rigidities
• Is the published economic evidence useful for decision makers?
Some examples of current work
Example I
Screening for Cystic Fibrosis
10
Economic evaluation of cystic fibrosis screening program• Cystic Fibrosis (CF) is one of the most common
serious genetic disease in Caucasians• Incidence of 1 in 2500 and carrier frequency of 1 in 25.
• In Australia, over 70 babies with CF are born mostly to parents with no known family history – No organized community based prenatal testing
programs– Calls for community screening of CF carriers
• Population screening strategies:• Preconception (before pregnancy)• Prenatal (during early pregnancy)• Neonatal (new born)
11
Aims
• Analyse the cost-effectiveness of a community-based cystic fibrosis (CF) carrier screening program– the cost of CF carrier screening per CF birth
averted.• Use decision analysis techniques• Attempted to look at literature
– Economic evidence– Transferability of existing evidences
12
Results - Economic Evidence
• 29 economic studies were included• North America (12), Europe(15), Asia/ Australia (2)• Only 14 studies focussed on preconceptional/ prenatal
screening
• Wide ranging Incremental Cost Effectiveness Ratio(ICER) – Cost per carrier couple detected ranged from
US$33,504 to US$295,121• Inconsistent net savings results (cost CF care
minus cost of CF screening) • Literature offers decision makers with limited
information and great uncertainty• How can we make better use of this evidence?
13
Deconstructing the model (1)Carrier (+)
Screening acceptance
(Single)
Carrier(-)
Normal Foetus
Screening acceptance (partner)
Carrier (+) Couple at
Risk
Acceptance for foetal diagnosis
CF affected foetus
Termination with no further reproduction
CF birth averted
Termination with healthy
foetus replacement
Delivery of affected CF
Child
Lifetime cost of care
for a CF child
14
Deconstructing the model (2)• Set inputs
– Carrier incidence (1/25 amongst Caucasians)– Carrier couple incidence (1/625 amongst Caucasians)– Foetus CF status (1/4 amongst CF+ carrier couples)
• Behavioural inputs– Screening participation:
• Preconception - 10% to 100%• Prenatal - 50% to 100%
– 15 -25% refrained from having children (preconception)– 75-100% make use of prenatal diagnosis– 80- 95% therapeutic termination rates– Decisions like in vitro fertilization ignored– Therapeutic termination range from 30 – 100%
15
Deconstructing the model (3)• Cost inputs
– Pre-screening stage• Mass communication - US$35k (in school screening) to
between US$297k - $562k (general population)– Screening stage
• Cost of per test – US$28 to US$240 – Post-test stage
• Counselling cost/carrier couple (US$17.2 to US$1188),CF foetal diagnosis(US$249 to US$2120),termination - US$206 to US$3486 and replacement (US$4,696)
– Lifetime cost of care of CF patients• Range from US$329k to US$1.3m• Estimated in several ways (specific to age, severity &
symptoms) and included different cost items (e.g. non-hospital costs)
16
Deconstructing the model (3)
• Identify fixed inputs• Identify behavioural inputs
– Assess the likelihood of variation with local setting– Where necessary substitute using
• Existing local evidence• New evidence where none exist
• Use local cost data from existing sources and standard methods
Example II
State of the art on the economics valuation of noise
project undertaken for the Department of Environment
and Climate Change NSW
18
Project aims
• Identify and assess methods for measuring the economic impact of noise pollution
• Appraise the potential for these methods for measuring noise in NSW
• Assess the applicability of empirical results of noise pollution to the NSW context– Here we focus on health
19
Project framework
• The nature of noise pollution– Multiple sources and impacts
• Context specific• Some evidence uncertain, others clear• Some impacts well-known, others unknown
– Multiple valuation techniques• Revealed preferences• Stated preferences• Physical linkages
– Preferred for the purposes of measuring health impact
20
Model deconstructionStep 1
Measure/model noisesource and levels
Step 2Estimate noise dispersion
by source and levels
Step 3Through exposure-response functions calculate impact
Step 4Estimate monetary value of
noise (e.g. welfare loss)
Step 1AMeasure change in noise levels
Step 3AMeasure change in impact
Step 2AMeasure change in noise
dispersion
Step 4AMeasure change in welfare
21
Empirical results: health costs
• Total health impact is a function of:– noise level– noise distribution– prevalence of disease– attributable fraction– cost of disease
• Health impact – Life years lost
– WTP to avoid disease
• Health care costs (cost of treatment/management)• Productivity costs (e.g. cost of days absent)
22
Exposure functions
• Noise can have an impact on:– Physiological responses including
stress and annoyance– Sleep disturbance – Hearing loss– Mental health– Child health– Cardiovascular disease– Performance and learning in children
23
Noise exposure functions
• State of the evidence– Good evidence on ‘annoyance’, ‘sleep
disturbance’ and ‘hearing loss’.– Some evidence on cardiovascular disease
and child learning and performance– Little or no evidence on serious mental
health and child health
• Future prospects of better and more conclusive evidence of relationships
24
Measuring the impact
• Staatsen et al (2004) estimated the monetary values for each health impact associated with noise as the sum of:
i. WTP to avoid each type of episode of ill health.
ii. health care costs of treatment when relevant; and
iii. productivity loss.
25
Empirical results: health costs
Source: Staatsen et al (2004)
Example III
Economic evaluation of Standard Cancer Treatment
Protocols UNSW and UTS
NHMRC Health Services Research Grant
27
Government spending on cancer drugs as a percentage of total (PBS/RBS)
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
28
Cancer-related pharmaceutical spending in public hospitals• $127m through Section 100 – highly
specialised drugs• $124m on drugs related to cancer
separations• 52% related to chemotherapy• Average pharmaceutical cost per chemo
separation:– 1996/97 = $165– 2004/05 = $479
29
The challenge in public hospitals• Capped budget; limited resources
– Maximise health– Very little information– Very little effective coordination
within/between hospitals
• Community and provider expectations– Teaching hospitals need to be at the cutting
edge– Clinical trials and Special Access Scheme
30
The challenge for public hospitals (and PHI)• Many new drugs• Far more costly • Far more complex
– Adoption decision– Cost-effective diffusion
• Introduced into a dysfunctional decision-making system
• Possible strategic behaviour by pharmaceutical companies
CI-SCAT
31
Cancer Institute– Standard Cancer Treatment protocols (NSW)
– Online resource that lists over 450 protocols– Information on target patient group, how to
administer the chemo drug, summary of evidence, dose calculation and side effects.
– Developed by multidisciplinary reference groups
www.cancerinstitute.org.au – But no economic evidence
32
Aims of the project
• Aim 1: Developing economic evidence for CI-SCaT clinical guidelines– similar to those produced for PBS funding– to present models that illustrate the costs
and consequences of implementing cancer treatment guidelines
– using existing data on cancer treatment pathways, as well as resource costs, to construct an economic “base case” against which new interventions can be compared.
33
Aims of the project• Aim 2: Developing economic evidence
applicable to local settings – work with local decision makers to adapt the
decision analytic models to the particular context of their locality.
– use local data to populate key model parameters – Models to set out the conditions necessary to
ensure that a new treatment remains cost-effective in practice.
• estimate the economic impact if prescribing patterns go beyond the intended patient groups,
• if treatment is not halted once certain clinical indicators have been reached.
• Aim 3: Have aims 1 and 2 had an impact?
34
The challenge
• 455 protocols (and counting); • Small budget, few health economists
and five years.• Economic evidence to be
– High quality– Timely– Relevant to local setting– Easily interpreted
35
The approach
• The decision context: – what type of chemotherapy to give – what additional (health) benefits can we expect at
what additional cost?• Outcome:
– survival but can also include quality of life– evidence from trials
• Resource use:– Cost of the drug - – Cost of administering – broad categories– Cost of managing side effects – general
econometric model
36
The approach
• Model to be available on web• Updated as new evidence is released• Estimates of additional resources (e.g. number of
chairs, nursing time)• Estimate of cost burden (e.g. federal government,
PHI, public hospital)• Local users can adapt model to take into account:
– Local population parameters– Local unit costs (e.g. wages)– Comparator– Alternative scenarios
37
Conclusions• Health economists place too much emphasis on the
results rather than the mechanics of the model.• Deconstruction would be useful – with more emphasis
on making general models available.• CI-SCAT project aims to produce economic evidence
that is: – Relevant and adaptable– High quality– Widely disseminated– Timely and regularly updated– Produced efficiently
• Will availability of economic evidence have an impact on decision-making?